Literature DB >> 29560535

Intrauterine growth restriction - impact on cardiovascular diseases later in life.

Carlos Menendez-Castro1, Wolfgang Rascher2, Andrea Hartner2.   

Abstract

Intrauterine growth restriction (IUGR) is a fetal pathology which leads to increased risk for certain neonatal complications. Furthermore, clinical and experimental studies revealed that IUGR is associated with a significantly higher incidence of metabolic, renal and cardiovascular diseases (CVD) later in life. One hypothesis for the higher risk of CVD after IUGR postulates that IUGR induces metabolic alterations that then lead to CVD.This minireview focuses on recent studies which demonstrate that IUGR is followed by early primary cardiovascular alterations which may directly progress to CVD later in life.

Entities:  

Keywords:  Cardiovascular disease; Fetal programming; Intrauterine growth restriction

Year:  2018        PMID: 29560535      PMCID: PMC5861253          DOI: 10.1186/s40348-018-0082-5

Source DB:  PubMed          Journal:  Mol Cell Pediatr        ISSN: 2194-7791


Background

Intrauterine growth restriction (IUGR) affects 3–7% of all newborns. As a consequence of maternal, placental or fetal pathology the fetus cannot fully exploit its growth potential [1]. While the term “small for gestational age” (SGA) describes a newborn with a birth weight less than the 10th percentile, IUGR requires a pathological retardation of intrauterine growth velocity clearly highlighted by a characteristic kink in the curve of intrauterine growth [2]. Newborns with IUGR exhibit significantly increased morbidity immediately after birth (e.g. hypoglycaemia, hypothermia, infant respiratory distress syndrome). Later in life former IUGR-patients were found to have a significantly higher incidence of renal, cardiovascular and metabolic diseases, the same ailments that are also the most frequent causes of morbidity and mortality in the western world [3-5]. The underlying mechanisms leading from fetal undersupply to the development of diseases in adulthood are not fully understood. In this context Barker et al. hypothesize that intrauterine undernutrition compromises growth and differentiation of organs during the vulnerable phase of fetal development that results in persistent alterations of the organism and leads to the development of secondary diseases later in life [6-8]. The shortage of nutrients during fetal development observed in IUGR is commonly replaced by an adequate nutrient supply after birth. The hypothesis of the “thrifty phenotype” considers the mismatch between intrauterine and postnatal supply with nutrients in IUGR individuals to be the underlying cause of secondary pathologies. In a fetus adapted to shortage of nutrients during intrauterine development postnatal hyperalimentation leads initially to excessive catch up growth and later to metabolic, cardiovascular and renal diseases [9]. As IUGR is associated with a higher incidence of metabolic syndrome, it appears conceivable that cardiovascular dysfunction observed after IUGR is secondary to diabetes, dyslipidemia or hypertension [10]. However, growing evidence suggests that IUGR directly causes cardiovascular alterations independent of pre-existing metabolic disease. Recent clinical and animal studies identified candidate mechanisms that may mediate the development of cardiovascular alterations in the setting of IUGR consistent with the hypothesis of perinatal programming [11, 12].

Myocardial function and structure after IUGR

In the heart, a number of studies revealed myocardial alterations induced by IUGR, that can be detected long before the onset of metabolic disease and arterial hypertension. IUGR affected cardiac development and significantly reduced the number of cardiomyocytes at the time of birth [13, 14]. Studies in humans revealed early and persistent alterations of myocardial structure and decreased cardiac function detected by echocardiography in fetal, neonatal and juvenile patients with IUGR [15-17]. These results were supported by findings in an animal model of IUGR exhibiting echocardiographic signs of cardiac dysfunction accompanied by a more distensible myocardium in the absence of arterial hypertension [18]. As a possible underlying mechanism, changes in the expression pattern of Titin (Ttn) after IUGR was observed: The passive elasticity of cardiomyocytes is modulated by alternative splicing of titin, a structural protein of the myocardial sarcomere, resulting in the two isoforms N2BA and N2B. Corresponding to the echocardiographic signs of a more distensible myocardium, relative overexpression of the less rigid isoform N2BA was observed in IUGR animals [18]. Moreover, assessment of inflammatory and profibrotic markers revealed an early induction of the expression of transforming growth factor beta (TGF-ß), connective tissue growth factor (CTGF) and microfibrillar matrix molecules in the myocardium of juvenile IUGR animals without evidence of metabolic syndrome [19]. This supports the notion of early and direct molecular changes in the cardiovascular system (Fig. 1).
Fig. 1

Direct and indirect pathways leading to cardiovascular disease in IUGR

Direct and indirect pathways leading to cardiovascular disease in IUGR

Atherosclerosis, vascular remodeling and fibrosis after IUGR

IUGR-induced metabolic disease (including dyslipidemia and insulin resistance) may likewise indirectly lead to atherosclerosis [10]. In addition, several studies provided evidence that IUGR is accompanied by early structural alterations in blood vessels [20-23]. Vascular remodeling favors the development of atherosclerosis [24]. In an animal model of vascular remodeling induced by unilateral ligation of the A. carotis communis significantly increased neointima formation and media thickness was observed in juvenile IUGR rats in the absence of metabolic disease [25]. Moreover, dedifferentiation of vascular smooth muscle cells (VSMC) was more prominent and collagen deposition in the media was increased after IUGR [25]. But even in the absence of experimental vascular disease, primary vascular alterations were detected in normotensive IUGR animals: A significantly increased expression of connective tissue growth factor (CTGF) was observed in aortas of neonatal animals after IUGR. Collagen I and collagen IV deposition in the aorta was more prominent in juvenile IUGR animals [19]. Recent studies examined IUGR-induced molecular mechanisms of endothelial dysfunction that favor the development of atherosclerosis. Oliveira et al. detected lower NO levels and increased eNOS phosphorylation in thoracic aortas of IUGR rats as a sign of endothelial dysfunction [26]. Taken together, these observations indicate that IUGR renders individuals more susceptible to the development of atherosclerotic lesions and vascular dysfunction and thus to cardiovascular-related diseases later in life.

Conclusions

IUGR favors the development of secondary cardiovascular diseases later in life which are among the most frequent causes of morbidity and mortality and constitute a significant proportion of healthcare-related expenditures in the western world. Cardiovascular disease appears not only to be a consequence of metabolic syndrome, but also caused by direct effects on cardiac and vasculature structure and function in individuals with IUGR. A more detailed knowledge of underlying disease mechanisms is likely to advance prevention and treatment of IUGR and its complications, and thereby improve long-term outcomes for patients with IUGR.
  26 in total

1.  Cell proliferation and cell death are disturbed during prenatal and postnatal brain development after uranium exposure.

Authors:  M Legrand; C Elie; J Stefani; C Culeux; O Delissen; C Ibanez; P Lestaevel; P Eriksson; C Dinocourt
Journal:  Neurotoxicology       Date:  2015-10-23       Impact factor: 4.294

Review 2.  The developmental origins of adult disease (Barker) hypothesis.

Authors:  Hendrina A de Boo; Jane E Harding
Journal:  Aust N Z J Obstet Gynaecol       Date:  2006-02       Impact factor: 2.100

3.  Cardiovascular function in children born very preterm after intrauterine growth restriction with severely abnormal umbilical artery blood flow.

Authors:  Eva Morsing; Petru Liuba; Vineta Fellman; Karel Maršál; Jana Brodszki
Journal:  Eur J Prev Cardiol       Date:  2013-04-23       Impact factor: 7.804

Review 4.  Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders.

Authors:  Radzislaw Mierzynski; Dominik Dluski; Dorota Darmochwal-Kolarz; Elzbieta Poniedziałek-Czajkowska; Bozena Leszczynska-Gorzelak; Zaneta Kimber-Trojnar; Jan Oleszczuk
Journal:  Curr Pharm Biotechnol       Date:  2016       Impact factor: 2.837

5.  Impaired myocardial performance in a normotensive rat model of intrauterine growth restriction.

Authors:  Carlos Menendez-Castro; Okan Toka; Fabian Fahlbusch; Nada Cordasic; Rainer Wachtveitl; Karl F Hilgers; Wolfgang Rascher; Andrea Hartner
Journal:  Pediatr Res       Date:  2014-03-06       Impact factor: 3.756

6.  Impaired vascular growth in late adolescence after intrauterine growth restriction.

Authors:  J Brodszki; T Länne; K Marsál; D Ley
Journal:  Circulation       Date:  2005-05-09       Impact factor: 29.690

7.  Fetal growth restriction results in remodeled and less efficient hearts in children.

Authors:  Fàtima Crispi; Bart Bijnens; Francesc Figueras; Joaquim Bartrons; Elisenda Eixarch; Ferdinand Le Noble; Asif Ahmed; Eduard Gratacós
Journal:  Circulation       Date:  2010-05-24       Impact factor: 29.690

8.  Short-term and long-term sequelae in intrauterine growth retardation (IUGR).

Authors:  Stefania Longo; Lina Bollani; Lidia Decembrino; Amelia Di Comite; Mauro Angelini; M Stronati
Journal:  J Matern Fetal Neonatal Med       Date:  2012-10-03

Review 9.  Human fetal growth restriction: a cardiovascular journey through to adolescence.

Authors:  A Sehgal; M R Skilton; F Crispi
Journal:  J Dev Orig Health Dis       Date:  2016-07-07       Impact factor: 2.401

10.  Prenatal and maternal characteristics and later risk for coronary heart disease among women.

Authors:  Johan G Eriksson; Eero Kajantie; Kent Thornburg; Clive Osmond
Journal:  Eur J Prev Cardiol       Date:  2015-07-07       Impact factor: 7.804

View more
  10 in total

1.  Lung function between 8 and 15 years of age in very preterm infants with fetal growth restriction.

Authors:  Michele Arigliani; Chiara Stocco; Elena Valentini; Carlo De Pieri; Luigi Castriotta; Maria Elena Ferrari; Cristina Canciani; Lorenza Driul; Maria Orsaria; Luigi Cattarossi; Paola Cogo
Journal:  Pediatr Res       Date:  2021-01-19       Impact factor: 3.756

Review 2.  Maternal Venous Hemodynamic Dysfunction in Proteinuric Gestational Hypertension: Evidence and Implications.

Authors:  Wilfried Gyselaers
Journal:  J Clin Med       Date:  2019-03-11       Impact factor: 4.241

3.  Impaired Progesterone-Responsiveness of CD11c+ Dendritic Cells Affects the Generation of CD4+ Regulatory T Cells and Is Associated With Intrauterine Growth Restriction in Mice.

Authors:  Kristin Thiele; Alexandra Maximiliane Hierweger; Julia Isabel Amambay Riquelme; María Emilia Solano; John P Lydon; Petra Clara Arck
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-25       Impact factor: 5.555

Review 4.  Aberrant Feeding and Growth in Neonates With Prenatal Opioid Exposure: Evidence of Neuromodulation and Behavioral Changes.

Authors:  Elizabeth Yen; Jill L Maron
Journal:  Front Pediatr       Date:  2022-01-21       Impact factor: 3.418

5.  Associations of maternal gestational hypertension with high blood pressure and overweight/obesity in their adolescent offspring: a retrospective cohort study.

Authors:  Renata Kuciene; Virginija Dulskiene
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

Review 6.  Maternal Low Volume Circulation Relates to Normotensive and Preeclamptic Fetal Growth Restriction.

Authors:  Wilfried Gyselaers; Christoph Lees
Journal:  Front Med (Lausanne)       Date:  2022-06-09

7.  Hyperactivation of Wnt/β-catenin and Jak/Stat3 pathways in human and zebrafish foetal growth restriction models: Implications for pharmacological rescue.

Authors:  Giovanni Risato; Rudy Celeghin; Raquel Brañas Casas; Alberto Dinarello; Alessandro Zuppardo; Andrea Vettori; Kalliopi Pilichou; Gaetano Thiene; Cristina Basso; Francesco Argenton; Silvia Visentin; Erich Cosmi; Natascia Tiso; Giorgia Beffagna
Journal:  Front Cell Dev Biol       Date:  2022-08-16

8.  Maternal investment, life-history trajectory of the off-spring and cardiovascular disease risk in Emirati females in the United Arab Emirates.

Authors:  Rola Al Ghali; Linda Smail; Maryam Muqbel; Dalia Haroun
Journal:  BMC Public Health       Date:  2021-06-27       Impact factor: 3.295

Review 9.  MicroRNAs in Uteroplacental Vascular Dysfunction.

Authors:  Xiang-Qun Hu; Lubo Zhang
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

Review 10.  Hypoxia and Mitochondrial Dysfunction in Pregnancy Complications.

Authors:  Xiang-Qun Hu; Lubo Zhang
Journal:  Antioxidants (Basel)       Date:  2021-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.